Nautilus Biotechnology (NAUT) Current Assets (2020 - 2026)

Nautilus Biotechnology (NAUT) has 7 years of Current Assets data on file, last reported at $98.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 30.2% year-over-year to $98.8 million; the trailing twelve-month figure through Mar 2026 stood at $98.8 million (down 30.2% YoY), and the FY2025 full-year result was $106.0 million, down 20.22% from the prior year.
• Current Assets eased to $98.8 million in Q1 2026, from $106.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $327.1 million in Q1 2022 to a low of $98.8 million in Q1 2026.
• A 5-year average of $179.1 million and a median of $170.5 million in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets surged 34856.29% in 2022 and tumbled 47.87% in 2023, its largest moves.
• Tracing NAUT's Current Assets over 5 years: stood at $187.2 million in 2022, then dropped by 5.54% to $176.8 million in 2023, then decreased by 24.89% to $132.8 million in 2024, then slipped by 20.22% to $106.0 million in 2025, then decreased by 6.73% to $98.8 million in 2026.
• Business Quant data shows NAUT's Current Assets at $98.8 million in Q1 2026, $106.0 million in Q4 2025, and $134.3 million in Q3 2025.